Sikiric, P., Kokot, A., Kralj, T., Zlatar, M., Masnec, S., Lazi, R., Lonari, K., Oroz, K., Sabli, M., Boljesic, M., Antunovi, M., Sikiri, S., trbe, S., Stambolija, V., Orekovi, B., Kavelj, I., Novosel, L., Zubcic, S., Krezic, I., krti, A., Jurjevi, I., Blagai, B., Seiwerth, S., & Stareini, M
Systematic reviews of BPC-157 in musculoskeletal applications identified 36 studies demonstrating improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injuries in preclinical models
Horses: The usual intravenous dosage is 2.5 to 5 mg (based on 3 mg per mL of dexamethasone content)
Weight regain is possible if caloric intake increases significantly or exercise decreases
In the obesity trial, maximal WL was achieved with retatrutide 12 mg after 48 weeks: -24.2% vs